Related Experiment Video
Updated: Jul 8, 2025
A Lectin HPLC Method to Enrich Selectively-glycosylated Peptides from Complex Biological Samples
Published on: October 1, 2009
Determination of alectinib and its active metabolite in plasma by pipette-tip solid-phase extraction using porous
Pengfei Zhang1, Wenyan Wang1, Junfa Yin2
1Hebei Key Laboratory of Public Health Safety, Key Laboratory of Medicinal Chemistry and Molecular Diagnosis of Ministry of Education, College of Pharmaceutical Science, College of Chemistry and Materials Science, Hebei University, Baoding 071002, China.
Abstract:
Alectinib is known as an effective targeted drug, which has excellent therapeutic effect on non-small cell lung cancer and can significantly prolong the survival of patients. Therapeutic drug monitoring is necessary due to the photo-instability of alectinib and the individual differences in patients. In this work, a porous polydopamine graphene oxide composite (PDAG) was prepared by a simple surface modification method. A PDAG-based pipette-tip solid-phase extraction (PT-SPE) coupled with HPLC-UV detection was proposed for the separation and detection of alectinib and its active metabolite M4 in plasma. The method was methodologically validated and showed good linearity in the range of 50-5000 ng mL-1 (R2 > 0.9995). The limit of detection (LOD) was 4.8 ng mL-1 and 3.9 ng mL-1 for alectinib and M4, respectively, and the limit of quantitation (LOQ) was 16.1 ng mL-1 and 13.1 ng mL-1, respectively. The intra-day and inter-day precision expressed by coefficient of variation was less than 4.8 %. The recovery of this method ranged from 84.9 % to 103.5 % with a standard deviation of less than 4.3 %. In conclusion, the established method is accurate, stable and inexpensive, and can be used to monitor the levels of alectinib and M4 in plasma, which provide technical and data support for exploring optimal individualized remedial dosing regimens.
Insights
A new method using a porous polydopamine graphene oxide composite (PDAG) allows for accurate monitoring of alectinib and its metabolite M4 in plasma. This technique supports personalized dosing for non-small cell lung cancer patients.
Area of Science:
- Analytical Chemistry
- Materials Science
- Pharmacology
Background:
- Alectinib is a crucial targeted therapy for non-small cell lung cancer (NSCLC).
- Therapeutic drug monitoring of alectinib is essential due to its photo-instability and patient variability.
- Accurate quantification of alectinib and its active metabolite M4 is needed for optimizing patient treatment.
Purpose of the Study:
- To develop and validate a sensitive method for simultaneous detection of alectinib and M4 in human plasma.
- To utilize a novel porous polydopamine graphene oxide composite (PDAG) for sample preparation.
- To establish a reliable tool for therapeutic drug monitoring to guide individualized dosing strategies.
Main Methods:
- Preparation of a porous polydopamine graphene oxide composite (PDAG).
- Development of a PDAG-based pipette-tip solid-phase extraction (PT-SPE) technique.
- Coupling PT-SPE with High-Performance Liquid Chromatography-Ultraviolet (HPLC-UV) detection for analysis.
Main Results:
- The method demonstrated excellent linearity (R² > 0.9995) in the range of 50-5000 ng/mL.
- Low limits of detection (LOD) and quantitation (LOQ) were achieved for both alectinib and M4.
- High precision (CV < 4.8%) and recovery (84.9%-103.5%) confirmed the method's reliability.
Conclusions:
- The developed PDAG-based PT-SPE coupled with HPLC-UV is an accurate, stable, and cost-effective method.
- This assay enables effective monitoring of alectinib and M4 plasma concentrations.
- Provides crucial data for optimizing individualized dosing regimens in NSCLC treatment.
